TG Therapeutics, Inc. (TGTX) key performance indicators and operating metrics (15 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| BRIUMVI United States net product revenue growth | 64.00 percent | FY2026-Q2 |
| BRIUMVI United States net product revenue sequential growth | 17.00 percent | FY2026-Q2 |
| Global patients prescribed BRIUMVI | 30K | FY2026-Q2 |
| BRIUMVI United States net product revenue | 227.7M | FY2026-Q2 |
| License, milestone, royalty, and other revenue | 4.5M | FY2026-Q2 |
| Operating expenses excluding noncash compensation | 150M | FY2026-Q2 |
| BRIUMVI sales to Neuraxpharm | 8.1M | FY2026-Q2 |
| Other research and development expense | 43.52M | FY2026-Q1 |
| Other selling, general, and administrative expense | 73.14M | FY2026-Q1 |
| Neuraxpharm commercialization-agreement royalty revenue | 3.6M | FY2026-Q2 |
| Neuraxpharm development and regulatory consideration | 900K | FY2026-Q2 |
| United States pre-variable-consideration net sales | 182.7M | FY2025-Q4 |
| Other revenue | 558K | FY2025-Q1 |
| License revenue | 2.39M | FY2025-Q3 |
Back to TGTX overview · TGTX earnings · TGTX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.